Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen: Patients Must Be At Center Of UK Biosimilar Decision Making

‘The NHS Is Under Capacity Pressure, We’re Asking For Change,’ Firm Says

Executive Summary

The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.

You may also be interested in...

UK Lays Out Reduced-Data Pathway For Biosimilars

The UK’s MHRA has laid out its plans for a biosimilar licensing pathway that will typically not require comparative efficacy data and will consider approved biosimilars interchangeable with their reference products for all indications. Local industry believes the guideline creates an opportunity for the UK to be the first launch market for biosimilars.

Bold Move To Embed Biosimilar Switching Aims To Bring Savings Of Up To £300m For NHS England

NHS England has produced a new framework intended to increase the use of biosimilars and generate savings of £200-300m on the drugs bill each year by 2020/21. An initial focus will be AbbVie’s Humira (adalimumab) and Roche’s Herceptin (trastuzumab), which are due to face biosimilar competition in the UK soon. Biosimilars firms have welcomed the move, but the R&D-based industry believes the savings targets set out in the document are unrealistic.

HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal

Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts